Paxalisib is the leading drug from NASDAQ-listed biotech, Kazia Therapeutics.
Paxalisib is the leading drug from NASDAQ-listed biotech, Kazia Therapeutics.
End of content
No more pages to load
From The Source
- DoHAC: Cost Recovery Implementation Statement (CRIS) – Administration of Private Health Insurance second-tier default benefits
- PBS: Drug Utilisation Sub-Committee (DUSC) Utilisation Analysis Public Release Documents
- New complaint against doctor previously accused of raping staff
- DoHAC: myGovID is now myID
- NSW Government funds research to help keep us safe from Legionnaires’ disease
- NSW Health: New therapeutic program to support vulnerable young families
- Bulli Hospital staff parking zone now open
- Victoria: New Designs Show Off The Future Of Health Care In Melton
- NSW Health: RPA Hospital Redevelopment supporting Aboriginal participation in construction
- Central Gippsland Health Service: Invitation to Supply – Fresh Meat and Fresh Poultry
- National Blood Authority: Provision of imported plasma and recombinant products
- Queensland Health Prosthetics Category: Standing Offer Arrangement (SOA) for provision of Orthopaedic Primary Joint Replacements